| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|---|
Equity Capital | 169.23 | 169.23 | 169.23 | 84.62 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 7,423.27 | 6,659.53 | 6,286.73 | 6,260.8 |
Net Worth | 7,592.5 | 6,828.76 | 6,455.96 | 6,345.42 |
Minority Interest | ||||
Debt | 2,629.02 | 3,344.2 | 4,575.47 | 3,347.51 |
Deferred Tax Liability Net | 916.33 | 1,063.59 | 1,014.15 | 990.42 |
Total Liabilities | 11,137.85 | 11,236.55 | 12,045.58 | 10,683.35 |
Fixed Assets | 7,955.88 | 8,212.15 | 8,669.78 | 6,818.75 |
Intangible Assets | ||||
Investments | 522.73 | 463.31 | 361.21 | 367.64 |
Deferred Tax Asset Net | 87.85 | 407.78 | 612.85 | 796.86 |
Networking Capital | 2,461.65 | 2,044.55 | 2,254.13 | 2,630.64 |
Inventories | 1,560.83 | 1,565.59 | 1,602.23 | 1,797.11 |
Inventory Days | 97.28 | |||
Sundry Debtors | 2,170.79 | 1,571.94 | 1,729.44 | 1,541.35 |
Debtor Days | 83.44 | |||
Other Current Assets | 521.79 | 454.84 | 361.66 | 558.25 |
Sundry Creditors | -798.41 | -779.3 | -654.8 | -639.56 |
Creditor Days | 34.62 | |||
Other Current Liabilities | -993.35 | -768.52 | -784.4 | -626.51 |
Cash | 109.74 | 108.76 | 147.61 | 69.46 |
Total Assets | 11,137.85 | 11,236.55 | 12,045.58 | 10,683.35 |
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
